<?xml version='1.0' encoding='utf-8'?>
<document id="28497258"><sentence text="Clinical Pharmacokinetics and Mass Balance of Veliparib in Combination with Temozolomide in Subjects with Nonhematologic Malignancies."><entity charOffset="46-55" id="DDI-PubMed.28497258.s1.e0" text="Veliparib" /><entity charOffset="76-88" id="DDI-PubMed.28497258.s1.e1" text="Temozolomide" /><pair ddi="false" e1="DDI-PubMed.28497258.s1.e0" e2="DDI-PubMed.28497258.s1.e0" /><pair ddi="false" e1="DDI-PubMed.28497258.s1.e0" e2="DDI-PubMed.28497258.s1.e1" /></sentence><sentence text="Veliparib is an orally active potent poly(ADP-ribose) polymerase (PARP) inhibitor currently in phase III clinical trials in solid tumors"><entity charOffset="0-9" id="DDI-PubMed.28497258.s2.e0" text="Veliparib" /></sentence><sentence text=" This phase I study evaluated the pharmacokinetics and mass balance of veliparib administered alone and in combination with temozolomide, and assessed any potential pharmacokinetic drug-drug interaction between veliparib and temozolomide"><entity charOffset="71-80" id="DDI-PubMed.28497258.s3.e0" text="veliparib" /><entity charOffset="124-136" id="DDI-PubMed.28497258.s3.e1" text="temozolomide" /><entity charOffset="211-220" id="DDI-PubMed.28497258.s3.e2" text="veliparib" /><entity charOffset="225-237" id="DDI-PubMed.28497258.s3.e3" text="temozolomide" /><pair ddi="false" e1="DDI-PubMed.28497258.s3.e0" e2="DDI-PubMed.28497258.s3.e0" /><pair ddi="false" e1="DDI-PubMed.28497258.s3.e0" e2="DDI-PubMed.28497258.s3.e1" /><pair ddi="false" e1="DDI-PubMed.28497258.s3.e0" e2="DDI-PubMed.28497258.s3.e2" /><pair ddi="false" e1="DDI-PubMed.28497258.s3.e0" e2="DDI-PubMed.28497258.s3.e3" /><pair ddi="false" e1="DDI-PubMed.28497258.s3.e1" e2="DDI-PubMed.28497258.s3.e1" /><pair ddi="false" e1="DDI-PubMed.28497258.s3.e1" e2="DDI-PubMed.28497258.s3.e2" /><pair ddi="false" e1="DDI-PubMed.28497258.s3.e1" e2="DDI-PubMed.28497258.s3.e3" /><pair ddi="false" e1="DDI-PubMed.28497258.s3.e2" e2="DDI-PubMed.28497258.s3.e2" /><pair ddi="false" e1="DDI-PubMed.28497258.s3.e2" e2="DDI-PubMed.28497258.s3.e3" /></sentence><sentence text="" /><sentence text="This was an open-label, dose-escalation study of veliparib in combination with temozolomide in 42 subjects with nonhematologic malignancies"><entity charOffset="49-58" id="DDI-PubMed.28497258.s5.e0" text="veliparib" /><entity charOffset="79-91" id="DDI-PubMed.28497258.s5.e1" text="temozolomide" /><pair ddi="false" e1="DDI-PubMed.28497258.s5.e0" e2="DDI-PubMed.28497258.s5.e0" /><pair ddi="false" e1="DDI-PubMed.28497258.s5.e0" e2="DDI-PubMed.28497258.s5.e1" /></sentence><sentence text=" Veliparib was administered orally at doses ranging from 10 to 80 mg twice daily on days 1-7, and temozolomide was administered orally at 150-200 mg/m2 once daily on days 1-5 of each 28-day cycle"><entity charOffset="1-10" id="DDI-PubMed.28497258.s6.e0" text="Veliparib" /><entity charOffset="98-110" id="DDI-PubMed.28497258.s6.e1" text="temozolomide" /><pair ddi="false" e1="DDI-PubMed.28497258.s6.e0" e2="DDI-PubMed.28497258.s6.e0" /><pair ddi="false" e1="DDI-PubMed.28497258.s6.e0" e2="DDI-PubMed.28497258.s6.e1" /></sentence><sentence text=" The pharmacokinetics of veliparib, its M8 metabolite, and temozolomide, as well as urinary excretion of unchanged veliparib and its M8 metabolite, were determined"><entity charOffset="25-34" id="DDI-PubMed.28497258.s7.e0" text="veliparib" /><entity charOffset="59-71" id="DDI-PubMed.28497258.s7.e1" text="temozolomide" /><entity charOffset="115-124" id="DDI-PubMed.28497258.s7.e2" text="veliparib" /><pair ddi="false" e1="DDI-PubMed.28497258.s7.e0" e2="DDI-PubMed.28497258.s7.e0" /><pair ddi="false" e1="DDI-PubMed.28497258.s7.e0" e2="DDI-PubMed.28497258.s7.e1" /><pair ddi="false" e1="DDI-PubMed.28497258.s7.e0" e2="DDI-PubMed.28497258.s7.e2" /><pair ddi="false" e1="DDI-PubMed.28497258.s7.e1" e2="DDI-PubMed.28497258.s7.e1" /><pair ddi="false" e1="DDI-PubMed.28497258.s7.e1" e2="DDI-PubMed.28497258.s7.e2" /></sentence><sentence text="" /><sentence text="Mean veliparib maximum observed plasma concentration (C max) and area under the plasma concentration-time curve for the first 6 h postdose (AUC6) values increased dose proportionally in the veliparib 10-80 mg twice-daily dose range"><entity charOffset="5-14" id="DDI-PubMed.28497258.s9.e0" text="veliparib" /><entity charOffset="190-199" id="DDI-PubMed.28497258.s9.e1" text="veliparib" /><pair ddi="false" e1="DDI-PubMed.28497258.s9.e0" e2="DDI-PubMed.28497258.s9.e0" /><pair ddi="false" e1="DDI-PubMed.28497258.s9.e0" e2="DDI-PubMed.28497258.s9.e1" /></sentence><sentence text=" The urinary recovery of veliparib dose as the unchanged parent compound alone and together with the M8 metabolite was 73 ± 18 and 90 ± 22%, respectively, over a 12-h dosing interval on day 6 of Cycle 1"><entity charOffset="25-34" id="DDI-PubMed.28497258.s10.e0" text="veliparib" /></sentence><sentence text=" Veliparib and temozolomide pharmacokinetic exposures were not affected when administered together"><entity charOffset="1-10" id="DDI-PubMed.28497258.s11.e0" text="Veliparib" /><entity charOffset="15-27" id="DDI-PubMed.28497258.s11.e1" text="temozolomide" /><pair ddi="false" e1="DDI-PubMed.28497258.s11.e0" e2="DDI-PubMed.28497258.s11.e0" /><pair ddi="false" e1="DDI-PubMed.28497258.s11.e0" e2="DDI-PubMed.28497258.s11.e1" /></sentence><sentence text="" /><sentence text="Veliparib is a Biopharmaceutical Classification System (BCS) Class 1 compound, with no less than 90% of the dose absorbed and an oral bioavailability of at least 73%"><entity charOffset="0-9" id="DDI-PubMed.28497258.s13.e0" text="Veliparib" /></sentence><sentence text=" Veliparib is primarily eliminated by renal excretion"><entity charOffset="1-10" id="DDI-PubMed.28497258.s14.e0" text="Veliparib" /></sentence><sentence text=" Veliparib exhibited linear pharmacokinetics in the 10-80 mg twice-daily dose range"><entity charOffset="1-10" id="DDI-PubMed.28497258.s15.e0" text="Veliparib" /></sentence><sentence text=" No pharmacokinetic interaction was observed when veliparib and temozolomide were administered together"><entity charOffset="50-59" id="DDI-PubMed.28497258.s16.e0" text="veliparib" /><entity charOffset="64-76" id="DDI-PubMed.28497258.s16.e1" text="temozolomide" /><pair ddi="false" e1="DDI-PubMed.28497258.s16.e0" e2="DDI-PubMed.28497258.s16.e0" /><pair ddi="false" e1="DDI-PubMed.28497258.s16.e0" e2="DDI-PubMed.28497258.s16.e1" /></sentence><sentence text="" /><sentence text="NCT00526617" /><sentence text="" /></document>